[Neurotransplantation in the treatment of Parkinson disease: follow-up].
The paper presents the results of follow-up of 11 patients with Parkinson's disease (PD) after neurotransplantation (NT) of fetal brain dopaminergic suspension into the caudatus and putamen on one or two sides. All the patients were clinically assessed at least 3 months before and during a follow-up (for as long as 9 years) in accordance with the Core Assessment Program for Intracranial Transplantation (CAPIT) by a Russian group of the Network of European CNS Transplantation and Restoration (NECTAR) Programme by using the Unified Parkinson's Disease Rating Scale (URDRS). An analysis of clinical findings showed that: 1) there was a slight amelioration in bradykinesia, rigidity, and smaller dosage of L-DOPA; 2) tremor and drug-induced dyskinesia remained unchanged; 3) subsequently (till 9 years), the clinical effect slightly decreased in almost all patients with PD and in some of them the clinical status became worse than that prior to surgery; 4) repeated NT (2 cases) in the striatum contralaterally did not improved the situation; 5) only neurostimulation of subcortical structures improved clinical results. So we can conclude that NT alone cannot be beneficial and requires additional interventions at the subcortical level.
Shabalov
V A
VA
Fedorova
N V
NV
Ugriumov
M V
MV
Popov
A P
AP
Shtok
V N
VN
Iakovleva
S A
SA
Arora
M
M
D000328:Adult; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001921:Brain / Q000196:embryology / Q000601:surgery; D016380:Brain Tissue Transplantation; D004298:Dopamine / Q000378:metabolism; D020820:Dyskinesias / Q000209:etiology; D004992:Ethics, Medical; D005260:Female; D016332:Fetal Tissue Transplantation; D005500:Follow-Up Studies; D006801:Humans; D018476:Hypokinesia / Q000209:etiology; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000209:etiology* / Q000601:surgery / Q000628:therapy*
D000978:Antiparkinson Agents; D007980:Levodopa; D004298:Dopamine